InVision has secured FDA breakthrough device designation for AI-enabled amyloidosis detection, integrating information from multiple echo views. The algorithm is the only peer-reviewed of its kind. The technology aims to shorten the journey to diagnosis for rare diseases. InpharmD, an Atlanta healthcare innovation, which uses AI and pharmacist expertise, has received an investment from AtlantaVentures to streamline treatment decisions. The FDA has granted breakthrough device designation to InVision's AI algorithm for aiding in the early identification of cardiac amyloidosis.
FDA InVision's AI algorithm for echocardiography, aiding in early cardiac amyloidosis diagnosis, receives FDA Breakthrough Device Designation. https://t.co/FFpa4JQ7fA This designation is for the algorithm designed to aid in the early identification of cardiac amyloidosis, a… https://t.co/AOuN3EUPqA
🚀 We're thrilled to announce our investment in InpharmD! This Atlanta healthcare innovation uses AI and pharmacist expertise to streamline treatment decisions, saving crucial time for patient care. Learn more here: https://t.co/oO4HqkLhNH
Congratulations to @bryandhe @David_Ouyang and @InVision_AI for receiving FDA breakthrough designation for using #echo #AI to detect #amyloidosis! https://t.co/NwtS3X1BVk
In parallel, congrats to @bryandhe and the @InVision_AI team for receiving @US_FDA breakthrough designation for #amyloidosis screening. We are excited about technologies that can shorten the journey to diagnosis for rare diseases. @Amyloidosis_ARC @ASE360 https://t.co/1gBZrmNiOP
We are excited to announce InVision has secured FDA breakthrough device designation for #ai enabled #amyloidosis detection. The AI algorithm integrates information from multiple #echofirst views and is the only peer reviewed algorithm of its kind. https://t.co/2s3NCLSDVa